English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Francisella tularensis , the causative agent of tularemia, is a category A bioterrorism agent. A vaccine that is safer and more effective than the currently available unlicensedF. tularensis live vaccine strain (LVS) is needed to protect against intentional release of aerosolizedF. tularensis , the most dangerous type of exposure. In this study, we employed a heterologous prime-boost vaccination strategy comprising intradermally administered LVS ΔcapB (highly attenuatedcapB -deficient LVS mutant) as the primer vaccine and rLm/iglC (recombinant attenuatedListeria monocytogenes expressing theF. tularensis immunoprotective antigen IglC) as the booster vaccine. Boosting LVS ΔcapB -primed mice with rLm/iglC significantly enhanced T cell immunity; their splenic T cells secreted significantly more gamma interferon (IFN-γ) and had significantly more cytokine (IFN-γ and/or tumor necrosis factor [TNF] and/or interleukin-2 [IL-2])-producing CD4+ and CD8+ T cells uponin vitro IglC stimulation. Importantly, mice primed with LVS ΔcapB or rLVS ΔcapB /IglC, boosted with rLm/iglC, and subsequently challenged with 10 50% lethal doses (LD50 ) of aerosolized highly virulentF. tularensis Schu S4 had a significantly higher survival rate and mean survival time than mice immunized with only LVS ΔcapB (P &lt; 0.0001); moreover, compared with mice immunized once with LVS, primed-boosted mice had a higher survival rate (75% versus 62.5%) and mean survival time during the first 21 days postchallenge (19 and 20 days for mice boosted after being primed with LVS ΔcapB and rLVS ΔcapB /IglC, respectively, versus 17 days for mice immunized with LVS) and maintained their weight significantly better (P &lt; 0.01). Thus, the LVS ΔcapB -rLm/iglC prime-boost vaccination strategy holds substantial promise for a vaccine that is safer and at least as potent as LVS.

infection and immunity

A Heterologous Prime-Boost Vaccination Strategy Comprising the Francisella tularensis Live Vaccine Strain<i>capB</i>Mutant and Recombinant Attenuated Listeria monocytogenes Expressing F. tularensis IglC Induces Potent Protective Immunity in Mice against Virulent F. tularensis Aerosol Challenge

A Heterologous Prime-Boost Vaccination Strategy Comprising the Francisella tularensis Live Vaccine StraincapBMutant and Recombinant Attenuated Listeria monocytogenes Expressing F. tularensis IglC Induces Potent Protective Immunity in Mice against Virulent F. tularensis Aerosol Challenge